| Name | Title | Contact Details |
|---|
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson`s disease (PD) and extending across the brain and affected organs.
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients needs. Hydromer collaborates extensively with clients to deliver superior, customized polymer-based solutions. We create or modify coating formulations that adhere to a multitude of substrates and match the unique requirements and geometries of any device. We are a leader in developing coating formulas and processes that meet a market-driven need for greener, more sustainable solutions. We offer custom industrial and medical device coatings, contract coating services, customized coating equipment, contract manufacturing, and turnkey operations backed by outstanding teams of research and development, customer service, and tech support. Hydromer`s technologies enhance the value of our clients products by delivering lubricity, thromboresistance, anti-fogging, antimicrobial, and other properties. Our coatings aid in the manufacture of medical devices, aerospace components, cosmetics, and products in a variety of industries. We are an FDA, GMP/ISO 13485, and ISO 9001 production facility.
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met.
Enzymatics is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.